Ani Pharmaceuticals (ANIP) Non-Current Assets (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Non-Current Assets data on file, last reported at $674.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 10.75% year-over-year to $674.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 billion (up 6.38% YoY), and the FY2025 full-year result was $687.3 million, down 9.09% from the prior year.
• Non-Current Assets declined to $674.9 million in Q1 2026, from $687.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $766.1 million in Q3 2024 to a low of $365.3 million in Q2 2024.
• A 5-year average of $536.8 million and a median of $429.7 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 102.68% in 2025 and retreated 10.75% in 2026, its largest moves.
• Tracing ANIP's Non-Current Assets over 5 years: stood at $415.8 million in 2022, then slipped by 7.51% to $384.6 million in 2023, then surged by 96.57% to $756.0 million in 2024, then dropped by 9.09% to $687.3 million in 2025, then declined by 1.8% to $674.9 million in 2026.
• Business Quant data shows ANIP's Non-Current Assets at $674.9 million in Q1 2026, $687.3 million in Q4 2025, and $709.8 million in Q3 2025.